Fresenius Kabi Oncology Ltd
Fresenius Kabi Oncology Limited engages in the development, manufacture, and marketing of chemotherapeutic drugs for the treatment of cancer.
- Market Cap ₹ Cr.
- Current Price ₹ 132
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 16.7
- Dividend Yield 0.00 %
- ROCE 7.80 %
- ROE 6.30 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 7.94 times its book value
- Company has a low return on equity of -20.2% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| 248 | 313 | 269 | 307 | 478 | 516 | |
| 223 | 295 | 277 | 446 | 455 | 427 | |
| Operating Profit | 25 | 18 | -8 | -139 | 23 | 89 |
| OPM % | 10% | 6% | -3% | -45% | 5% | 17% |
| 4 | 21 | 185 | 53 | 14 | 14 | |
| Interest | 3 | 8 | 15 | 29 | 32 | 32 |
| Depreciation | 6 | 7 | 19 | 28 | 32 | 34 |
| Profit before tax | 20 | 24 | 143 | -143 | -27 | 37 |
| Tax % | 19% | 19% | 31% | 2% | 21% | 56% |
| 16 | 20 | 99 | -146 | -33 | 16 | |
| EPS in Rs | 1.26 | 6.29 | -9.23 | -2.11 | 1.01 | |
| Dividend Payout % | 19% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 24% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -44% |
| TTM: | 149% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -20% |
| Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 288 | 308 | 421 | 266 | 232 | 248 |
| 189 | 266 | 298 | 432 | 577 | 676 | |
| 60 | 79 | 122 | 133 | 245 | 221 | |
| Total Liabilities | 553 | 668 | 858 | 846 | 1,070 | 1,161 |
| 139 | 365 | 412 | 487 | 470 | 517 | |
| CWIP | 224 | 139 | 123 | 3 | 58 | 99 |
| Investments | 4 | 3 | 54 | 0 | 0 | 0 |
| 187 | 162 | 268 | 357 | 542 | 545 | |
| Total Assets | 553 | 668 | 858 | 846 | 1,070 | 1,161 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| 17 | 9 | -28 | -187 | -72 | 3 | |
| -90 | -132 | 8 | 54 | -66 | -122 | |
| 125 | 74 | 33 | 141 | 150 | 102 | |
| Net Cash Flow | 51 | -49 | 13 | 8 | 12 | -17 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 68 | 99 | 119 | 98 | 82 |
| Inventory Days | 304 | 258 | 425 | 642 | 448 | 584 |
| Days Payable | 169 | 161 | 271 | 228 | 298 | 248 |
| Cash Conversion Cycle | 198 | 165 | 252 | 533 | 248 | 418 |
| Working Capital Days | 103 | 93 | 160 | 242 | 197 | 219 |
| ROCE % | 4% | 23% | -18% | 1% | 8% |
Documents
Announcements
No data available.